View Older Stories

May 6, 2026 06:00PM InMed Reports Third Quarter Fiscal 2026 Financial Results and Provides Business Update

Apr 27, 2026 05:30PM InMed Pharmaceuticals Amends Preferred Investment Options

Mar 27, 2026 05:06PM InMed Pharmaceuticals gets Nasdaq notice on minimum bid price

Mar 27, 2026 05:05PM InMed Pharmaceuticals Receives Nasdaq Notification Regarding Minimum Bid Price Compliance

Mar 23, 2026 07:32AM InMed reports positive brain organoid data for alzheimer's drug INM-901

Mar 23, 2026 07:30AM InMed Pharmaceuticals Announces Positive Data from Human Brain Organoid Neuroinflammation Models Supporting the INM-901 Alzheimer's Disease Program

Mar 9, 2026 07:30AM InMed Provides Update on Pharmaceutical Development Programs - Advancing Lead Drug Candidates Towards IND and Clinical Trial

Mar 6, 2026 05:04PM InMed Provides Update on BayMedica Operations and Strengthens Focus on Pharmaceutical Development Pipeline

Feb 11, 2026 05:23PM InMed Reports Second Quarter Fiscal 2026 Financial Results and Provides Business Update

Dec 17, 2025 08:00PM InMed Announces Results of 2025 Annual General and Special Meeting

Dec 12, 2025 05:31PM InMed Provides Update on BayMedica Commercial Business

Nov 18, 2025 07:32AM InMed completes pharmacokinetic studies for Alzheimer's drug candidate

Nov 18, 2025 07:30AM InMed Announces Successful Completion of Pharmacokinetic Studies in Large Animal Model for Its Alzheimer's Disease Candidate INM-901

Nov 6, 2025 04:51PM InMed Reports First Quarter Fiscal 2026 Financial Results and Provides Business Update

Oct 16, 2025 08:32AM InMed Pharmaceuticals adds John Bathery to board of directors

Oct 16, 2025 08:30AM Inmed Pharmaceuticals Appoints Mr. John Bathery to Its Board of Directors

Oct 14, 2025 06:07AM InMed Pharmaceuticals appoints Neil Klompas to board of directors

Oct 9, 2025 08:32AM InMed Pharmaceuticals names Neil Klompas to board of directors

Oct 9, 2025 08:30AM InMed Pharmaceuticals Appoints Mr. Neil Klompas to It's Board of Directors

Sep 23, 2025 08:30AM InMed Pharmaceuticals Reports Full Year Fiscal 2025 Financial Results and Provides Business Update

Sep 5, 2025 09:33AM InMed to Participate in the H.C. Wainwright 27th Annual Global Investment Conference

Aug 1, 2025 06:05AM InMed Pharmaceuticals Inc. (INM) Files for 3.9M Share Offering by Selling Stockholders

Jul 28, 2025 07:00AM InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025

Jun 27, 2025 07:00AM InMed Pharmaceuticals Announces Closing of $5 Million Private Placement Priced At-the-Market under Nasdaq Rules

Jun 25, 2025 08:03AM InMed Pharmaceuticals Inc. (INM) Announces 1.95M Share Offering at $2.561/sh

Jun 25, 2025 08:00AM InMed Pharmaceuticals Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq Rules

Jun 24, 2025 07:02AM InMed Pharmaceuticals (INM) Announces INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

Jun 24, 2025 07:00AM InMed's INM-901 Significantly Reduces Neuroinflammation in Alzheimer's Disease Ex Vivo Study

Jun 13, 2025 04:30PM InMed Appoints CBIZ as New Auditor in Connection with CBIZ's Acquisition of Marcum's Attest Business, Provides Update on Special Meeting and Makes Modifications to Existing SEPA

May 13, 2025 06:46AM InMed Pharmaceuticals Inc. (INM) Misses Q3 EPS by 194c

May 12, 2025 06:00PM InMed Reports Third Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 13, 2025 04:08AM InMed Pharmaceuticals Inc. (inm) Misses Q2 EPS by 364c

Feb 13, 2025 04:05AM InMed Pharmaceuticals Inc. (inm) Misses Q2 EPS by 364c

Feb 12, 2025 06:54PM InMed Reports Second Quarter Fiscal 2025 Financial Results and Provides Business Update

Feb 3, 2025 07:33AM InMed Pharmaceuticals Inc. (INM) Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

Feb 3, 2025 07:30AM InMed Announces INM-089 Intravitreal Formulation in the Treatment of Dry Age-Related Macular Degeneration

Jan 22, 2025 07:32AM InMed Pharmaceuticals Inc. (INM) Granted Patent for Novel Compounds

Jan 22, 2025 07:30AM InMed Pharmaceuticals Announces Granting of Patent for Novel Compounds

Jan 21, 2025 07:34AM InMed Pharmaceuticals' (INM) INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Jan 21, 2025 07:30AM InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study

Dec 23, 2024 05:18PM InMed Pharmaceuticals Inc. (INM) Files for 3M Share Offering by Selling Stockholders

Dec 18, 2024 08:00PM InMed Announces Results of 2024 Annual General Meeting

Dec 17, 2024 04:58PM InMed Pharmaceuticals (INM) Enters $10M Standby Equity Purchase Agreement

Dec 17, 2024 04:56PM InMed Enters Into Standby Equity Purchase Agreement

Nov 19, 2024 07:30AM InMed Announces Publication of Study on Anti-Inflammation by Modulation of Endocannabinoid System

Nov 14, 2024 09:14PM InMed Pharmaceuticals Inc. (INM) Reports Q1 Loss of $2.17

Nov 14, 2024 04:45PM InMed Reports First Quarter Fiscal 2025 Financial Results and Provides Business Update

Nov 8, 2024 04:44PM InMed Announces Share Consolidation to Satisfy Nasdaq Listing Rules

Nov 5, 2024 08:32AM InMed Pharmaceuticals Inc. (INM) Granted Nasdaq Exception to Implement Share Consolidation

Nov 5, 2024 08:30AM InMed Pharmaceuticals Announces Decision by NASDAQ Hearings Panel to Grant Exception to Implement Share Consolidation to Satisfy NASDAQ Listing Rules

View Older Stories